News Conference News ACC 2026 Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b Yael L. Maxwell April 01, 2026
News Conference News ACC 2026 Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering Michael O'Riordan April 01, 2026
News Conference News ACC 2026 SCOUT-HCM: Mavacamten Can Benefit Teens With Obstructive HCM, Too Caitlin E. Cox March 30, 2026
News Conference News ACC 2026 SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients Michael O'Riordan March 30, 2026
News Conference News ACC 2026 SPIRIT-HF: Spironolactone’s Benefit Still Uncertain in HF With Preserved, Mildly Reduced EF Todd Neale March 29, 2026
News Conference News ACC 2026 PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV Michael O'Riordan March 29, 2026
News Conference News ACC 2026 Barbershop Effort Falls Short for Hypertension Prevention in Black Men Todd Neale March 29, 2026
News Conference News ACC 2026 Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE Yael L. Maxwell March 28, 2026
News Conference News ACC 2026 KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension Caitlin E. Cox March 28, 2026
News Conference News ACC 2026 CHAMPION-AF: A Win for Watchman FLX, but With Caveats Todd Neale March 28, 2026
News Conference News ACC 2026 Mechanical Circulatory Support Doesn’t Reduce Infarct Size in STEMI Michael O'Riordan March 28, 2026
Presentation ACC 2026 Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation: The CHAMPION-AF Clinical Trial Presenter: Saibal Kar March 28, 2026
News Conference News ACC 2025 ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a) L.A. McKeown April 10, 2025
News Conference News ACC 2025 FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints L.A. McKeown April 03, 2025
News Conference News ACC 2025 RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI Michael O'Riordan April 02, 2025
News Conference News ACC 2025 Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP Michael O'Riordan April 01, 2025
News Conference News ACC 2025 Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI Caitlin E. Cox March 30, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
Presentation ACC 2025 STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes Presenter: Marc P. Bonaca March 29, 2025